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PCR restriction-fragment-length-polymorphism (PCR-RFLP)
assay, we determined them by RDB hybridization assay
again and the samples were sequenced directly in cases
with inconsistent results. 40 samples with consistent results
were randomly selected and sequenced directly.
Results: 36 samples were inconsistent with each other by
RDB hybridization assay and PCR-RFLP. Since no products
could get by PCR, 14 (14/36) samples with inconsistent
results could not be sequenced. Total of 62 samples were
sequenced (the rest 22 samples with inconsistent results
and 40 samples randomly selected), whose coincidence rate
was 96.77% (60/62), compared to RDB hybridization assay.
Combined result of sequencing, coincidence rate of RDB
hybridization assay was signiﬁcantly higher compared to
that of PCR-RFLP (X2 = 16.4, P< 0.05).
Conclusions: The RDB hybridization assay we established
could identify YMDD mutation in a single assay with
reliability and speciﬁcity, and especially had the superiority
of high speciﬁcity for mixed infection. Furthermore, the
results were easier to be judged by eyes directly. RDB
hybridization assay was a better method for mixed infection
of HBV YMDD motif than PCR-RFLP and DNA direct
sequencing. It has a great potential of application because
of making operation even more simple and cost-savings.
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Objective: To evaluate PCR product pyrosequencing in
detecting genotypic resistance of adefovir in chronic
hepatitis B (CHB) patients.
Methods: Serum and clinical data of CHB patients who
had taken ADV mono-therapy were collected, they were
once underwent viral breakthrough or could not achieve
virological response after at least 48 weeks therapy. ADV
associated mutations including rtA181V/T and rtN236T
were detected by pyrosequencing. Resistance and ratio of
mutants were analyzed with software of sequencer. PCR
product di-deoxy sequencing was also used for analysis of
ADV resistance. And resistantce proﬁles get from two assays
were compared.
Results: 210 CHB patients were tested. Totally 67
ADV resistance patients and 92 mutants were detected.
64 patients were positive for ADV resistance by
pyrosequencing, and 52 cases by di-deoxy sequencing, the
coincidence of the two approaches was 83.8%. there were
44 patients who had single mutants, 26 of them had a ratio
of mutants <50%.
Conclusions: Pyrosequencing is effective in detecting
adefovir resistance. Adefovir resistance mutant clones may
not be the dominant in the population even in breakthrough
patients.
Table 1. Pyrosequencing and di-deoxy sequencing for detecting adefovir
resistance
Mutation Pyrosequencing Di-deoxy sequencing
rtA181T 26 19
rtA181V 11 12
rtN236T 7 2
rtA181V/T 1 1
rtA181T+rtN236T 9 10
rtA181V+rtN236T 8 8
rtA181V/T+rtN236T 2 0
Total 64 52
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Background and Objectives: Adefovir dipivoxil (AD) can
make over 20% HBeAg-positive chronic hepatitis B (CHB)
patients’ HBVDNA loads be reduced to undetectable levels
after one years treatment. Many CHB patients’ HBVDNA
relapsed after stopping therapy. The selection of durations
and endpoints of treatment is important and difﬁcult issues.
This study evaluates duration treatment time via modeling
the dynamics of AD anti-HBV infection therapy.
Methods: A total of 39 HBeAg-positive CHB patients with
baseline HBVDNA >105 copies/mL and ALT >2ULN received
AD (10mg/day) in a multicenter, randomized, double-
blind study. Patients were treated for 96 weeks. Using a
differential equation model (L. Min et al., in Proc. IASTED
Int. Conf. Modelling, Simulation, and Identiﬁcation 2009,
659 057) simulated the course of patients HBVDNA levels.
Results: At the endpoint, about 23% (9/39) patients had
HBVDNA <250 cp/mL (the detection lower limit) and
ALT became normalization. About 38% (15/39) patients’s
HBVDNA levels were breakthrough. About 38% (15/39)
patients’ HBVDNA levels were not reduced to be less
250cp/mL. Simulated the course of HBVDNA for 4 patients
who had high baseline HBVDNA (>107 cp/mL) and HBVDNA
<250cp/mL at the endpoint. Results shown that the
simulated data of our models were agrement with in the
experimental ones. The simulations shown that it needed
about 18 years to replace the patients infected hepatocytes
by normal ones.
Conclusion: For high baseline HBVDNA level CHB patients,
AD may not be an idea monotone ﬁrst line anti-HBV infection
therapy drug. Entecavir may be a more promising candidate
to treat such kind of CHB patients.
Acknowledgments: This work is supported by the Yong
Science Research Foundation of Beijing Healthy Bureau (No.
QN2008 033).
PP-133 Molecular study of HCV detection, genotypes
and their routes of transmission in North West
Frontier Province (N.W.F.P.) of Pakistan
S. Zaman Saﬁ1 *, I. Qadri1. 1NUST Center of Virology and
immunology, National University of Science and Technology,
Pakistan
Very little is known about the epidemiological
manifestation, genotypes and risk factors of HCV infection
in North West Frontier Province (N.W.F.P) of Pakistan.
Therefore, the subject study was conducted to determine
HCV genotypes and to explore the associated risk factors
in chronic HCV patients. 116 chronic HCV patients were
enrolled for qualitative analysis by PCR out of which 112
chronic HCV patients (53, 47.32% males and 59, 52.68%
females) with mean age 43.76±16.4 and mean BMI 23.8±3.9
were included in this study. Frequency of six HCV genotypes
and associated risk factors were evaluated from ﬁve districts
of N.W.F.P.
Genotype 3 was the most prevalent in 73 samples (65.17%)
followed by genotype 1 in 24 (21.42%) and genotype 2
in 13 (11.60%) samples. Genotype 3 has signiﬁcantly high
prevalence (P= 0.0002). 48 (42.85%) samples were proved
as HCV 3a; 25 (22.32%) 3b; 14 (12.5%) 1a; 10 (08.92%) 1b; 11
(09.82%) 2a; 2 (1.78%) 2b and 2 Untypable. HCV genotype
3a, 3b, 2a, 1a, 1b were most prevalent in Nowshehra,
Peshawar, Mardan, Sawabi and Mardan respectively. HCV
